INDV — Indivior Pharmaceuticals Inc stock price, charts and financials

QT76Indivior Pharmaceuticals Inc

Indivior Pharmaceuticals Inc (NASDAQ: INDV) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
38.31
-0.51-1.31%
OverviewShort InterestFilings
INDVQT76Indivior Pharmaceuticals Inc·NASDAQ
38.31-1.31%
TA
Loading chart...
Signal & projected range
Insider buy + earnings beatHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
OCTVV+0.00%$17.48AMRX-1.16%$17.93LNTH-0.11%$100.84SUPN-1.86%$46.76RGC-1.17%$5.35BHC+3.84%$6.49RDY-1.19%$12.07HCM+0.40%$12.56
Snapshot
Index-P/E13.67EPS (ttm)2.84Insider Own1.86%Shs Outstand124.77MPerf Week-2.97%
Market Cap4.84BForward P/E8.80EPS next Y4.41Insider Trans-3.04%Shs Float112.13MPerf Month-6.00%
Enterprise Value5.13BPEG0.07EPS next Q-Inst Own-Short Float10.06%Perf Quarter-1.97%
Income353.58MP/S3.64EPS this Y103.99%Inst Trans-Short Ratio5.75Perf Half Y12.69%
Sales1.33BP/B-EPS next Y9.25%ROA28.79%Short Interest11.28MPerf YTD8.19%
Book/sh-P/C-EPS next 5Y5.03%ROE-216.13%52W High42.25 -9.32%Perf Year76.45%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC125.11%52W Low21.41 78.98%Perf 3Y71.54%
Dividend Est.-EV/EBITDA11.88Sales past 3/5Y11.20% 13.88%Gross Margin83.86%Volatility6.25% 4.01%Perf 5Y234.66%
Dividend TTM-EV/Sales3.85EPS Y/Y TTM13100.00%Oper. Margin38.89%ATR (14)1.64Perf 10Y121.83%
Dividend Ex-DateJun 16, 2016Quick Ratio0.66Sales Y/Y TTM8.67%Profit Margin26.65%RSI (14)46.56Recom2.00
Dividend Gr. 3/5Y-Current Ratio0.84EPS Q/Q134.15%SMA20-2.34%Beta1.11Target Price48.00
Payout0.00%Debt/Eq-Sales Q/Q19.17%SMA50-0.89%Rel Volume0.85Prev Close38.82
Employees833LT Debt/Eq-3.18EarningsOct 29SMA20011.54%Avg Volume1.99MPrice38.31
IPO DateDec 29, 2014Option/ShortYes / YesEPS/Sales Surpr.45.45% 16.19%Net Debt/EBITDA0.66Volume1,687,034Change-1.31%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-05-26ReiteratedBarclaysOverweight$46 → $43
Aug-04-26ReiteratedCraig-HallumBuy$50 → $53
Jun-18-26InitiatedBarclaysOverweight$46
Jan-20-26ReiteratedNorthland Securities$40 → $50
Jan-12-26ReiteratedHC Wainwright & Co.Buy$35 → $48
Dec-03-25ReiteratedMorgan Stanley$28 → $36
Oct-31-25ReiteratedCraig-HallumBuy$34 → $41
Oct-31-25ReiteratedNorthland Securities$30 → $40
Oct-30-25ReiteratedHC Wainwright & Co.Buy$35
Aug-27-25ReiteratedCraig-HallumBuy$20 → $34
Latest News
Aug-07-26
Aug-07-2612:00PM
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPNgurufocus.com
Aug-04-26
Aug-04-2601:21PM
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlookzacks.com
Aug-03-26
Aug-03-2603:44PM
Supernus And Indivior Merger: There May Be Some Skepticism, But I Have Faith In This DealSeekingAlpha
03:15PM
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV)prnewswire.com
12:14PM
Supernus Pharmaceuticals (SUPN) Announces Transformative Merger with Indivior (INDV)gurufocus.com
10:44AM
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenuebenzinga.com
10:44AM
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholdersbusinesswire.com
08:46AM
Indivior Pharmaceuticals Inc. (INDV) Q2 Earnings and Revenues Beat Estimateszacks.com
07:33AM
Supernus, Indivior merge to strengthen neuroscience drug portfolioreuters.com
06:31AM
Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidanceglobenewswire.com
Jul-23-26
Jul-23-2610:00AM
Indivior to Report Second Quarter 2026 Financial Results and Host Webcastglobenewswire.com
Jul-21-26
Jul-21-2610:32AM
Billionaire Investor Howard Marks' Top 5 Holdings: A Buy at These Prices?247wallst.com
Jul-17-26
Jul-17-2610:00AM
INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) Shows Breakout Setup With Perfect Technical Strength ScoreChartMill
Jun-29-26
Jun-29-2609:56AM
Indivior Pharmaceuticals Inc. (INDV) is on the Move, Here's Why the Trend Could be Sustainablezacks.com
Jun-18-26
Jun-18-2608:49AM
Barclays Initiates Coverage On Indivior Pharmaceuticals with Overweight Rating, Announces Price Target of $46Benzinga
Company

Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,3321,2391,188——————
Cost of Goods Sold Incl. D&A215246231——————
Gross Profit1,117993957——————
Selling, General and Administrative Excl. Other534634618——————
Research and Development6597107——————
Other Operating Expense0-3200——————
Operating Income51826532——————
Interest Expense274541——————
Unusual Expense
—————————
Non-Operating Income (Expense)-981923——————
Net Income Before Taxes39323914——————
Income Taxes382911——————
Consolidated Net Income3552102——————
Net Income From Continuing Operations3552103——————
Net Income3552102——————
EPS (Recurring)2.841.680.02——————
EPS (Basic, Before Extraordinaries)2.841.680.02——————
EPS (Diluted)2.791.640.02——————
EBITDA43230484——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio13.7321.88828.67——————
Price To Sales Ratio3.603.621.38——————
Gross Margin83.8680.1580.56——————
Operating Margin38.8921.392.69——————
Net Margin26.6516.950.17——————
Shares Outstanding125125132——————
Market Capitalization4,7894,4851,641——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$46.24$36.68$27.12$17.56$8.00● Close Price0.00M0.52M1.03M1.55M2.06MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Anderson Woodrow DChief Accounting OfficerAug 05 '26Buy36.281,50054,42026,138Aug 05
Heidbreder ChristianChief Scientific OfficerJul 10 '26Sale41.1418,586764,628209,337Jul 13
Ciaffoni JosephChief Executive OfficerJun 22 '26Option Exercise0.001,266,90301,402,879Jun 23
Heidbreder ChristianChief Scientific OfficerJun 11 '26Sale38.0618,586707,383227,923Jun 12
Preblick RyanChief Financial OfficerJun 08 '26Sale37.7036,0001,357,200284,751Jun 10
Preblick RyanChief Financial OfficerMar 14 '26Option Exercise0.006,3020323,594Mar 17
Ryan BarbaraDirectorMar 13 '26Buy31.0982495,724Mar 13
Ryan BarbaraDirectorMar 09 '26Buy32.56311,0095,716Mar 11
Kingsley Stuart ADirectorMar 06 '26Buy31.8694029,9535,582Mar 11
Anderson Woodrow DChief Accounting OfficerMar 03 '26Option Exercise0.0048,285029,657Mar 05
Preblick RyanChief Financial OfficerMar 03 '26Option Exercise0.00200,4590317,292Mar 05
Burris Jeffrey WChief Legal OfficerMar 03 '26Option Exercise0.00184,1930107,550Mar 05
Heidbreder ChristianChief Scientific OfficerMar 03 '26Option Exercise0.00234,1090292,306Mar 05
Ryan BarbaraDirectorJan 05 '26Buy35.3977527,4291,963Jan 07
Humphreys KeithDirectorJan 05 '26Buy35.3977527,4295,802Jan 07
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.